Novo Nordisk, a leading global healthcare company, has announced the signing of a MoU with Lifera, a biopharmaceutical ...

The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

Novo Nordisk now has an Ozempic pill. Citing a Novo spokesperson, pharmaceuticals news site BioPharmaDive reported yesterday ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

The MOU marks a significant step in strengthening the Kingdom’s healthcare sector and pharmaceutical manufacturing ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

Big compounders will have until May 22 to stop producing and dispensing compounded semaglutide, while smaller, state-run ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...